


Teva-sponsored virtual symposium

**MIGRAINE
TRUST
VIRTUAL
SYMPOSIUM
2020**

Join online
Monday 5 October
18:30–20:00 GMT

ADVANCES IN MIGRAINE PREVENTION: WHAT'S NEW?



teva

ADVANCES IN MIGRAINE PREVENTION: WHAT'S NEW?

**MIGRAINE
TRUST
VIRTUAL
SYMPOSIUM
2020**

WELCOME

Dear colleagues,

With great pleasure, I invite you to join us at this Teva-sponsored satellite symposium, taking place during the Migraine Trust Virtual Symposium 2020.

The efficacy of anti-CGRP monoclonal antibodies has been clearly established. As data continue to emerge from clinical trials, now is the time to focus on individual migraine patients and the challenges they encounter.

During this virtual symposium, we will consider the treatment decisions faced when managing patients with difficult-to-treat migraine, and will discuss how we can apply the latest subgroup data from patients enrolled in anti-CGRP monoclonal antibody trials to the patients we encounter in our clinics. Looking to the future, we will also provide an update on some of the latest research in CGRP signalling, focusing on novel information and future directions in research.

I hope you will join us for what promises to be an engaging and informative symposium.



Patricia Pozo-Rosich, Chair
Vall d'Hebron University Hospital
Barcelona, Spain

To register for the Migraine Trust Virtual Symposium, please visit <https://www.mtis2020.org>. The symposium will include the opportunity to ask questions to the faculty throughout the presentations.

PROGRAMME



Welcome

Patricia Pozo-Rosich, Spain
(Chair)




Case discussion: How can we improve the lives of patients with difficult-to-treat migraine?

Christian Lamp, Austria



Targeted therapies: targeted evidence – anti-CGRP monoclonal antibodies in difficult-to-treat migraine

Tim Jürgens, Germany



Neuropeptide targets in migraine pathophysiology – what does the latest research tell us and what do we still need to learn?

Anthony Dickenson, UK



Panel discussion and closing remarks

Facilitated by
Patricia Pozo-Rosich